| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2001;32:553.)
© 2001 American Heart Association, Inc.
Original Contributions |
Human Albumin Therapy of Acute Ischemic Stroke
Marked Neuroprotective Efficacy at Moderate Doses and With a Broad Therapeutic Window
From the Cerebral Vascular Disease Research Center, Department of Neurology, University of Miami School of Medicine, Miami, Fla.
Correspondence to Myron D. Ginsberg, MD, Department of Neurology (D4-5), University of Miami School of Medicine, PO Box 016960, Miami, FL 33101. E-mail mdginsberg{at}stroke.med.miami.edu
Background and Purpose—We examined the neuroprotective efficacy of moderate-dose human albumin therapy in acute focal ischemic stroke and defined the therapeutic window after stroke onset, within which this therapy would confer neurobehavioral and histopathological neuroprotection.
Methods—Sprague-Dawley rats were anesthetized with halothane/nitrous oxide and received 2-hour middle cerebral artery occlusion (MCAo) by a poly-L-lysine–coated intraluminal suture. Neurological status was evaluated during occlusion (60 minutes) and daily for 3 days after MCAo. In the dose-response study, human albumin doses of either of 0.63 or 1.25 g/kg or saline vehicle (5 mL/kg) were given intravenously immediately after suture removal. In the therapeutic window study, a human albumin dose of 1.25 g/kg was administered intravenously at 2 hours, 3 hours, 4 hours, or 5 hours after onset of MCAo. Three days after MCAo, brains were perfusion-fixed, and infarct volumes and brain swelling were determined.
Results—Moderate-dose albumin therapy significantly improved the neurological score at 24 hours, 48 hours, and 72 hours and significantly reduced total infarct volume (by 67% and 58%, respectively, at the 1.25- and 0.63-g/kg doses). Cortical and striatal infarct volumes were also significantly reduced by both doses. Brain swelling was virtually eliminated by albumin treatment. Even when albumin therapy (1.25 g/kg) was initiated as late as 4 hours after onset of MCAo, it improved the neurological score and markedly reduced infarct volumes in cortex (by 68%), subcortical regions (by 52%), and total infarct (by 61%).
Conclusions—Moderate-dose albumin therapy markedly improves neurological function and reduces infarction volume and brain swelling, even when treatment is delayed up to 4 hours after onset of ischemia.
Key Words: brain edema • cerebral ischemia, focal • hemodilution • middle cerebral artery occlusion • neuroprotection
This article has been cited by other articles:
 |
|
 |
|
  M. D. Ginsberg Current Status of Neuroprotection for Cerebral Ischemia: Synoptic Overview Stroke, March 1, 2009; 40(3_suppl_1): S111 - S114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Simard, V. Yurovsky, N. Tsymbalyuk, L. Melnichenko, S. Ivanova, and V. Gerzanich Protective Effect of Delayed Treatment With Low-Dose Glibenclamide in Three Models of Ischemic Stroke * Supplemental Methods Stroke, February 1, 2009; 40(2): 604 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Philip, M. Benatar, M. Fisher, and S. I. Savitz Methodological Quality of Animal Studies of Neuroprotective Agents Currently in Phase II/III Acute Ischemic Stroke Trials Stroke, February 1, 2009; 40(2): 577 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Cook, A. Peppard, and B. Magnuson Nutrition Considerations in Traumatic Brain Injury Nutr Clin Pract, December 1, 2008; 23(6): 608 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. Chang, Y.-F. Tsai, P.-J. Lin, M.-C. Chen, and C.-Y. Liu Prevalence and Risk Factors for Postoperative Delirium in a Cardiovascular Intensive Care Unit Am. J. Crit. Care., November 1, 2008; 17(6): 567 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-P. Park, A. Nimmagadda, R. A. DeFazio, R. Busto, R. Prado, and M. D. Ginsberg Albumin Therapy Augments the Effect of Thrombolysis on Local Vascular Dynamics in a Rat Model of Arteriolar Thrombosis: A Two-Photon Laser-Scanning Microscopy Study Stroke, May 1, 2008; 39(5): 1556 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nimmagadda, H.-P. Park, R. Prado, and M. D. Ginsberg Albumin Therapy Improves Local Vascular Dynamics in a Rat Model of Primary Microvascular Thrombosis: A Two-Photon Laser-Scanning Microscopy Study Stroke, January 1, 2008; 39(1): 198 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. V. Arumugam, S.-C. Tang, J. D. Lathia, A. Cheng, M. R. Mughal, S. Chigurupati, T. Magnus, S. L. Chan, D.-G. Jo, X. Ouyang, et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death PNAS, August 28, 2007; 104(35): 14104 - 14109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg Life After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post-NXY-059 Era Stroke, June 1, 2007; 38(6): 1967 - 1972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg and M. D. Hill Response to Letter by Parkkinen et al Stroke, February 1, 2007; 38(2): 256 - 256. [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg, M. D. Hill, Y. Y. Palesch, K. J. Ryckborst, and D. Tamariz The ALIAS Pilot Trial: A Dose-Escalation and Safety Study of Albumin Therapy for Acute Ischemic Stroke--I: Physiological Responses and Safety Results Stroke, August 1, 2006; 37(8): 2100 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y. Palesch, M. D. Hill, K. J. Ryckborst, D. Tamariz, and M. D. Ginsberg The ALIAS Pilot Trial: A Dose-Escalation and Safety Study of Albumin Therapy for Acute Ischemic Stroke--II: Neurologic Outcome and Efficacy Analysis Stroke, August 1, 2006; 37(8): 2107 - 2114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Allport, M. W. Parsons, K. S. Butcher, L. MacGregor, P. M. Desmond, B. M. Tress, and S. M. Davis Elevated hematocrit is associated with reduced reperfusion and tissue survival in acute stroke Neurology, November 8, 2005; 65(9): 1382 - 1387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Ley, A. Vigdorchik, L. Belayev, W. Zhao, R. Busto, L. Khoutorova, D. A. Becker, and M. D. Ginsberg Stilbazulenyl Nitrone, a Second-Generation Azulenyl Nitrone Antioxidant, Confers Enduring Neuroprotection in Experimental Focal Cerebral Ischemia in the Rat: Neurobehavior, Histopathology, and Pharmacokinetics J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1090 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Belayev, I. Saul, R. Busto, K. Danielyan, A. Vigdorchik, L. Khoutorova, and M. D. Ginsberg Albumin Treatment Reduces Neurological Deficit and Protects Blood-Brain Barrier Integrity After Acute Intracortical Hematoma in the Rat Stroke, February 1, 2005; 36(2): 326 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Belayev, V. L. Marcheselli, L. Khoutorova, E. B. Rodriguez de Turco, R. Busto, M. D. Ginsberg, and N. G. Bazan Docosahexaenoic Acid Complexed to Albumin Elicits High-Grade Ischemic Neuroprotection Stroke, January 1, 2005; 36(1): 118 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Evidence-based Colloid Use in the Critically Ill: American Thoracic Society Consensus Statement Am. J. Respir. Crit. Care Med., December 1, 2004; 170(11): 1247 - 1259. [Full Text] [PDF]
|
|
|
|
|
|
R. C. Seet, E. C. Lim, B. P. Chan, B. K. Ong, and T. Dziedzic Serum Albumin Level as a Predictor of Ischemic Stroke Outcome Stroke, November 1, 2004; 35(11): 2435 - 2436. [Full Text] [PDF]
|
|
|
|
|
|
T. Dziedzic, A. Slowik, and A. Szczudlik Serum Albumin Level as a Predictor of Ischemic Stroke Outcome Stroke, June 1, 2004; 35(6): e156 - e158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Gum, R. A. Swanson, C. Alano, J. Liu, S. Hong, P. R. Weinstein, and S. S. Panter Human Serum Albumin and its N-Terminal Tetrapeptide (DAHK) Block Oxidant-Induced Neuronal Death Stroke, February 1, 2004; 35(2): 590 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Belayev, L. Khoutorova, T. A. Deisher, A. Belayev, R. Busto, Y. Zhang, W. Zhao, and M. D. Ginsberg Neuroprotective Effect of SolCD39, a Novel Platelet Aggregation Inhibitor, on Transient Middle Cerebral Artery Occlusion in Rats Stroke, March 1, 2003; 34(3): 758 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-M. Muchitsch, H. P. Schwarz, M. D. Ginsberg, L. Belayev, and R. Busto Beneficial Effect of Albumin Therapy Attributable to {alpha}1-Acid Glycoprotein? Stroke, January 1, 2003; 34(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ginsberg Adventures in the Pathophysiology of Brain Ischemia: Penumbra, Gene Expression, Neuroprotection: The 2002 Thomas Willis Lecture Stroke, January 1, 2003; 34(1): 214 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shuaib, C. Xu Wang, T. Yang, and R. Noor Effects of Nonpeptide V1 Vasopressin Receptor Antagonist SR-49059 on Infarction Volume and Recovery of Function in a Focal Embolic Stroke Model Stroke, December 1, 2002; 33(12): 3033 - 3037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.R. Caplan Worsening in Ischemic Stroke Patients: Is it Time for a New Strategy? Stroke, June 1, 2002; 33(6): 1443 - 1445. [Full Text] [PDF]
|
|
|
|
|
|
L. Belayev, E. Pinard, H. Nallet, J. Seylaz, Y. Liu, P. Riyamongkol, W. Zhao, R. Busto, and M. D. Ginsberg Albumin Therapy of Transient Focal Cerebral Ischemia: In Vivo Analysis of Dynamic Microvascular Responses Stroke, April 1, 2002; 33(4): 1077 - 1084. [Abstract] [Full Text] [PDF]
|
|